PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY APPLICATION • Market segmentation by application • Comparison by application • Solid tumors - Market size and forecast 2018-2023 • Blood-related tumors - Market size and forecast 2018-2023 • Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AstraZeneca • Bristol-Myers Squibb • F. Hoffmann-La Roche • Merck • Pfizer PART 13: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Years in consideration Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Application - Market share 2018-2023 (%) Exhibit 19: Comparison by application Exhibit 20: Solid tumors - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Approved PD-1 and PD-L1 inhibitors for various indications: Overview Exhibit 22: Solid tumors - Year-over-year growth 2019-2023 (%) Exhibit 23: Blood-related tumors - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Blood-related tumors - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by application Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 36: ROW - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Decision framework Exhibit 40: New cases of cancer in US 2015 Exhibit 41: Impact of drivers and challenges Exhibit 42: PD-1 and PD-L1 inhibitors pipeline: Overview Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: AstraZeneca - Vendor overview Exhibit 49: AstraZeneca - Business segments Exhibit 50: AstraZeneca - Organizational developments Exhibit 51: AstraZeneca - Geographic focus Exhibit 52: AstraZeneca - Key offerings Exhibit 53: AstraZeneca - Key customers Exhibit 54: Bristol-Myers Squibb - Vendor overview Exhibit 55: Bristol-Myers Squibb - Business segments Exhibit 56: Bristol-Myers Squibb - Organizational developments Exhibit 57: Bristol-Myers Squibb - Geographic focus Exhibit 58: Bristol-Myers Squibb - Key offerings Exhibit 59: Bristol-Myers Squibb - Key customers Exhibit 60: F. Hoffmann-La Roche - Vendor overview Exhibit 61: F. Hoffmann-La Roche - Business segments Exhibit 62: F. Hoffmann-La Roche - Organizational developments Exhibit 63: F. Hoffmann-La Roche - Geographic focus Exhibit 64: F. Hoffmann-La Roche - Segment focus Exhibit 65: F. Hoffmann-La Roche - Key offerings Exhibit 66: F. Hoffmann-La Roche - Key customers Exhibit 67: Merck - Vendor overview Exhibit 68: Merck - Business segments Exhibit 69: Merck - Organizational developments Exhibit 70: Merck - Geographic focus Exhibit 71: Merck - Segment focus Exhibit 72: Merck - Key customers Exhibit 73: Pfizer - Vendor overview Exhibit 74: Pfizer - Business segments Exhibit 75: Pfizer - Organizational developments Exhibit 76: Pfizer - Geographic focus Exhibit 77: Pfizer - Segment focus Exhibit 78: Pfizer - Key offerings Exhibit 79: Pfizer - Key customers Exhibit 80: Validation techniques employed for market sizing Exhibit 81: List of abbreviations  

AstraZeneca Bristol-Myers Squibb F. Hoffmann-La Roche Merck Pfizer